Tumor resistance to protein kinase inhibitors.

Abstract

Cancer treatment is difficult, there are many issues regarding cancer treatment because Protein Kinase Inhibitors (PKIs) are unable to control tumors that are resistant to them. Resistance to drugs starts with changes in genetic code and continues with fresh changes, routes and alterations in the tumour. When treating cancer with imatinib or osimertinib, PKIs can correct faulty signals, yet patients generally become resistant swiftly and this resistance can include unpleasant side effects. Reviewing Epidermal Growth Factor Receptor (EGFR) T790M and BCR::ABL1 T315I mutations reveals that the important interactions and binding sites are removed or obstructed with the drug. This is how researchers design second- and third-generation drug inhibitors. In addition, the use of single-cell sequencing, CRISPR screens and liquid biopsies helps researchers and doctors to accurately fight resistance in cancer patients. For cancer treatments to succeed, systems to reduce drug costs and make them available, fresh ideas, global experts and equitable healthcare laws should be implemented.